Repositioning Candidate Details
| Candidate ID: | R1477 |
| Source ID: | DB13153 |
| Source Type: | approved; experimental |
| Compound Type: | small molecule |
| Compound Name: | Levomenol |
| Synonyms: | (-)-alpha-Bisabolol; alpha-(-)-bisabolol; alpha-bisabolol; Bisabolol; Kamillosan; Levomenol; α-(−)-bisabolol |
| Molecular Formula: | C15H26O |
| SMILES: | [H][C@@]1(CCC(C)=CC1)[C@@](C)(O)CCC=C(C)C |
| Structure: |
|
| DrugBank Description: | Bisabolol, or more formally α-(−)-bisabolol or also known as levomenol, (-)-alpha-Bisabolol is found in fats and oils. (-)-alpha-Bisabolol is isolated from essential oil of Matricaria chamomilla (German chamomile) (-)-alpha-Bisabolol belongs to the family of Sesquiterpenes. These are terpenes with three consecutive isoprene units. |
| CAS Number: | 23089-26-1 |
| Molecular Weight: | 222.372 |
| DrugBank Indication: | Levomenol has been known to elicit a number of potentially beneficial pharmacological effects, including anti-irritant, anti-inflammatory, and anti-microbial actions. Bisabolol is also demonstrated to enhance the percutaneous absorption of certain molecules |
| DrugBank Pharmacology: | Levomenol is an anti-inflammatory and natural moisturizing agent that has been found to diminish the signs of photodamage, reduce pruritus, and ameliorate skin texture and elasticity. |
| DrugBank MoA: | -- |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|